Join
Live feed
·
PRReleasevia Quantisnow
Compass Therapeutics Inc. logo

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CMPX· Compass Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CMPX (Compass Therapeutics Inc.) and more on Quantisnow.